Answers are grounded in this paper and cite their sources.
Perioperative neurocognitive disorders (PND) represent one of the major challenges in the rehabilitation of elderly surgical patients. Their occurrence results from the complex interplay of surgical stress, patient vulnerability, and anesthetic drugs. Traditional review models, which categorize by drug class, fragment the holistic picture of how anesthetics act upon shared pathophysiological networks, making it difficult to decipher the common basis and differential roots of their heterogeneous cognitive effects. This narrative review integrates animal and in vitro studies with human physiological studies, observational cohorts, randomized trials, and evidence syntheses. It proposes an integrative framework, the “Pathophysiological Axis-Drug Action Map,” aimed at systematically deconstructing the origins of the heterogeneous cognitive effects of different anesthetic agents. This framework focuses on four core axes: 1) Neuroinflammation and Immune Regulation, 2) Neural Network Synchrony and Synaptic Plasticity, 3) Sleep-Wake Cycle and Brain Homeostasis, and 4) Epigenetic Programming and Long-term Vulnerability. Predominantly preclinical evidence suggests that different drugs can exert divergent effects on the same pathological axis (e.g., dexmedetomidine suppresses neuroinflammation, whereas sevoflurane may exacerbate it), while the same drug can have interwoven benefits and drawbacks across different axes (e.g., propofol combines reported anti-inflammatory properties with context-dependent sleep effects). These mechanism-based differences in “pharmacological portraits” may contribute to their context-dependent clinical risk–benefit profiles. Matching drug combinations to patients’ putative vulnerabilities, including inflammatory or genetic profiles, is proposed as a research hypothesis rather than a prospectively validated clinical decision algorithm. Future studies should identify perioperative biomarkers and explore multi-axis neuroprotective strategies whose combined effects require testing. Prospective human validation is required before the framework can inform clinical drug selection.
No takes yet. Share an insight, caveat, or question.
Xiao et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: